Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

CertaraJune 9, 2026

Blog

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

CertaraJune 9, 2026

Video

Applying AI-Driven Biosimulation to Drug Discovery

Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…

CertaraJune 2, 2026

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-BodnarMay 28, 2026

Blog

Certainty US 2026 recap: advancing model-informed drug development right from the start

This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…

CertaraMay 26, 2026

Publication

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

CertaraMay 21, 2026

On-Demand Webinar

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Learn how Phoenix NLME and RsNLME support advanced PK/PD workflows and complex pharmacometric modeling through…

CertaraMay 20, 2026

On-Demand Webinar

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

See how Phoenix NLME and RsNLME support scalable and manageable workflows as project demands evolve.

Danielle PillsburyMay 8, 2026

Blog

What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= May 8, 2026 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…

CertaraMay 8, 2026

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

CertaraMay 7, 2026

Modeling and Simulation – PK/PD

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Applying AI-Driven Biosimulation to Drug Discovery

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

Certainty US 2026 recap: advancing model-informed drug development right from the start

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD

Designing Drug Development Programs for Reimbursement Success

Newsletter sign up

Quick links

Solutions

Contact